Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer

被引：18

作者：

Rossi, Antonio ^{[1
]}

La Salvia, Anna ^{[2
]}

Di Maio, Massimo ^{[3
]}

机构：

[1] IRCCS Casa Sollievo Sofferenza, Div Med Oncol, Viale Cappuccini 1, I-71013 San Giovanni Rotondo, FG, Italy

[2] Univ Turin, San Luigi Gonzaga Hosp, Dept Oncol, Orbassano, TO, Italy

[3] Univ Turin, Ordine Mauriziano Hosp, Dept Oncol, Turin, Italy

来源：

EXPERT REVIEW OF RESPIRATORY MEDICINE | 2017年 / 11卷 / 03期

关键词：

Afatinib; chemotherapy; EGFR; erlotinib; gefitinib; icotinib; metastatic; mutations; NSCLC; tyrosine kinase inhibitor; RANDOMIZED PHASE-II; EGFR MUTATIONS; OPEN-LABEL; 1ST-LINE TREATMENT; INTERMITTENT ERLOTINIB; COMPARING ERLOTINIB; ACQUIRED-RESISTANCE; COMBINATION; THERAPY; TRIAL;

D O I：

10.1080/17476348.2017.1290526

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Introduction: Preclinical data showed that intercalated administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective in the treatment of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss the clinical results available to date from prospective studies investigating this approach. Areas covered: A structured search of bibliographic databases for peer-reviewed literature and of main International meetings was undertaken, for trials testing the intercalated addition of EGFR-TKIs to chemotherapy in advanced NSCLC. Expert commentary: The results of intercalated schedules of EGFR-TKI and chemotherapy are interesting but somewhat contrasting. This approach could represent a potential treatment option in patients with advanced NSCLC, that deserves to be further investigated within well-designed randomized trials.

引用

页码：171 / 180

页数：10

共 60 条

[1] A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study† [J].

Aerts, J. G. ;

Codrington, H. ;

Lankheet, N. A. G. ;

Burgers, S. ;

Biesma, B. ;

Dingemans, A. -M. C. ;

Vincent, A. D. ;

Dalesio, O. ;

Groen, H. J. M. ;

Smit, E. F. .

ANNALS OF ONCOLOGY, 2013, 24 (11) :2860-2865

[2]

[Anonymous], J CLIN ONCOL

[3] Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed [J].

Chen, Chung-Yu ;

Chang, Yih-Leong ;

Shih, Jin-Yuan ;

Lin, Jou-Wei ;

Chen, Kuan-Yu ;

Yang, Chih-Hsin ;

Yu, Chong-Jen ;

Yang, Pan-Chyr .

LUNG CANCER, 2011, 74 (01) :132-138

[4] Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy [J].

Chen, Yuh-Min ;

Liu, Jacqueline Ming ;

Chou, Teh-Ying ;

Perng, Reury-Perng ;

Tsai, Chun-Ming ;

Whang-Peng, Jacqueline .

CANCER, 2007, 109 (09) :1821-1828

[5] In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines [J].

Cheng, Hua ;

An, She-Juan ;

Zhang, Xu-Chao ;

Dong, Song ;

Zhang, Yi-Fang ;

Chen, Zhi-Hong ;

Chen, Hua-Jun ;

Guo, Ai-Lin ;

Lin, Qiu-xiong ;

Wu, Yi-Long .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (03) :637-646

[6] Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations [J].

Cheng, Ying ;

Murakami, Haruyasu ;

Yang, Pan-Chyr ;

He, Jianxing ;

Nakagawa, Kazuhiko ;

Kang, Jin Hyoung ;

Kim, Joo-Hang ;

Wang, Xin ;

Enatsu, Sotaro ;

Puri, Tarun ;

Orlando, Mauro ;

Yang, James Chih-Hsin .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) :3258-+

[7] Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer [J].

Fang, Hong ;

Lin, Rong-Yan ;

Sun, Ming-Xia ;

Wang, Qian ;

Zhao, Yu-Liang ;

Yu, Jing-Lin ;

Tian, Yan ;

Wang, Xiao-Yun .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (24) :10967-10970

[8] EGFR mutations in lung cancer: from tissue testing to liquid biopsy [J].

Fenizia, Francesca ;

De Luca, Antonella ;

Pasquale, Raffaella ;

Sacco, Alessandra ;

Forgione, Laura ;

Lambiase, Matilde ;

Iannaccone, Alessia ;

Chicchinelli, Nicoletta ;

Franco, Renato ;

Rossi, Antonio ;

Morabito, Alessandro ;

Rocco, Gaetano ;

Piccirillo, Maria Carmela ;

Normanno, Nicola .

FUTURE ONCOLOGY, 2015, 11 (11) :1611-1623

[9] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Dikshit, Rajesh ;

Eser, Sultan ;

Mathers, Colin ;

Rebelo, Marise ;

Parkin, Donald Maxwell ;

Forman, David ;

Bray, Freddie .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386

[10] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial [J].

Gatzemeier, Ulrich ;

Pluzanska, Anna ;

Szczesna, Aleksandra ;

Kaukel, Eckhard ;

Roubec, Jaromir ;

De Rosa, Flavio ;

Milanowski, Janusz ;

Karnicka-Mlodkowski, Hanna ;

Pesek, Milos ;

Serwatowski, Piotr ;

Ramlau, Rodryg ;

Janaskova, Terezie ;

Vansteenkiste, Johan ;

Strausz, Janos ;

Manikhas, Georgy Moiseevich ;

Von Pawel, Joachim .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1545-1552

← 1 2 3 4 5 6 →